Austar LifesciencesAULSF 49 EBITDA Margin % is 2.67% as of Dec. 2025, which is 46% below its 10-year median of 4.94. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.10. The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Austar Lifesciences ranks worse than 56.62% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Austar Lifesciences EBITDA Margin % Related Terms
Austar Lifesciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AULSF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Austar Lifesciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a EBITDA Margin % of 2.67% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Austar Lifesciences and its competitors. This is 46% below median its historical median of 4.94. According to the industry distribution chart, Austar Lifesciences ranks #462 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 56.6%.
Is Austar Lifesciences' EBITDA Margin % too high?
Austar Lifesciences' current EBITDA Margin % of 2.67% is 46% below median its 10-year median of 4.94. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Austar Lifesciences' value of 2.67% is 64.3% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #462 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #462 out of 816 companies for EBITDA Margin %. This places Austar Lifesciences in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Austar Lifesciences' value of 2.67% is 64.3% below this benchmark. While the company's 10-year median is 4.94 vs. the industry median of 7.48, Austar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current EBITDA Margin % of 2.67% is 64.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current EBITDA Margin % is 2.67%, which is 46% below median its own 10-year median of 4.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current EBITDA Margin % of 2.67%. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30% below its estimated fair value. The current EBITDA Margin % is 2.67%, which is 46% below median its 10-year median of 4.94 and 64.3% below the Medical Devices & Instruments industry median of 7.48. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current EBITDA Margin % is 2.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.07 is trading 30% below its estimated GF Value™ of $0.10.
Key valuation signals for AULSF:
EBITDA Margin %: 2.67% (46% below median its 10-year median of 4.94)
GF Value™: $0.10 vs. price of $0.07 (30% below fair value)
Industry Position: 64.3% below the Medical Devices & Instruments median (#462 of 816)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
